Table 1.

Associations between seven lncRNAs and clinical features

Variables	n	SNHG1 (mean±s.d.)	P	CRNDE (mean±s.d.)	P	CTC-296K1.4 (mean±s.d.)	P	UBXN10-AS1 (mean±s.d.)	P	PART 1 (mean±s.d.)	P	CTC-296K1.3 (mean±s.d.)	P	PGM5-AS1 (mean±s.d.)	P
Age at diagnosis (year)			0.02		0.52		0.24		0.24		<0.01		0.12		0.46
<60	190	9.40±0.37		7.23±0.29		4.14±0.27		2.34±0.30		10.50±0.57		6.39±0.39		11.10±0.93
≥60	267	10.60±0.32		7.00±0.22		3.74±0.22		1.68±0.12		7.70±0.33		5.61±0.32		10.15±0.85
T stage			<0.01		<0.01		0.04		<0.01		<0.01		0.01		<0.01
T1 + T2	175	8.89±0.30		6.09±0.22		4.34±0.29		2.72±0.33		10.26±0.47		6.77±0.41		14.22±1.22
T3 + T4	277	10.92±0.34		7.76±0.25		3.61±0.21		1.47±0.11		7.99±0.41		5.38±0.31		8.11±0.65
Lymph node status			<0.01		<0.01		0.02		0.01		0.01		0.01		<0.01
N0	317	9.78±0.28		6.74±0.19		3.96±0.20		1.83±0.13		8.98±0.39		5.88±0.29		10.56±0.75
N1	73	11.98±0.73		9.25±0.60		2.92±0.33		1.11±0.19		6.65±0.70		4.27±0.48		5.05±0.84
Metastasis			0.36		0.99		0.20		0.50		0.45		0.16		0.30
M0	420	10.07±0.25		7.17±0.19		3.89±0.17		1.99±0.15		8.79±0.33		5.91±0.25		10.71±0.67
M1	2	13.41±6.05		7.21±2.74		0.67±0.46		0.49±0.41		5.19±3.07		0.84±0.62		0.73±0.33
Gleason score			<0.01		<0.01		<0.01		<0.01		<0.01		<0.01		<0.01
<7	43	8.90±0.55		5.59±0.34		5.78±0.72		4.15±1.07		10.40±0.91		9.26±1.06		20.54±3.09
=7	233	8.74±0.28		6.45±0.21		4.11±0.24		2.15±0.17		9.97±0.47		6.26±0.34		11.69±0.84
>7	181	12.14±0.44		8.28±0.33		3.20±0.24		1.18±0.11		7.07±0.42		4.72±0.34		6.68±0.78

s.d.: standard deviation; SNHG1: small nucleolar RNA host gene 1; CRNDE: colorectal neoplasia differentially expressed; PART 1: prostate androgen-regulated transcript 1; PGM5-AS1: phosphoglucomutase 5 antisense RNA 1; CTC: RNA-Glu; UBXN10-AS1: ubiquitin-binding protein domain protein 10 antisense RNA 1